Atsutaka Yasui

Head of Cardio-Renal-Metabolism

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Atsutaka Yasui is the Head of Cardio-Renal-Metabolism at Nippon Boehringer Ingelheim Co., Ltd. in Japan. His research focuses on cardiovascular health and diabetes management, as evidenced by his recent publications on heart failure screening, the impact of empagliflozin on cardiovascular events, and safety studies involving diabetic patients. Dr. Yasui is actively involved in investigating the effectiveness of SGLT2 inhibitors and their role in organ protection.

Articles (9)

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (4)

Kento Kitada

Kagawa University

JAPAN

View details

Dae Jung Kim

professor

Ajou University School of Medicine

SOUTH KOREA

View details

Masaomi Nangaku

Graduate School of Medicine, The University of Tokyo

JAPAN

View details

Daisuke Yabe

Director and Professor

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Atsutaka Yasui

Research Interests

Explore related searches

Contact this professor

About

Articles (9)

An evidence-based tool for screening for heart failure with preserved ejection fraction in primary care: The BREATH2 score

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study

Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study

The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non‐Asian populations of the EMPA‐REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease

Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium-glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabetes.

Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation.

Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study

Safety and tolerability of empagliflozin and linagliptin combination therapy in patients with type 2 diabetes mellitus: a pooled analysis of data from five randomized, controlled clinical trials

Validity of Claims Diagnosis Codes for Cardiovascular Diseases in Diabetes Patients in Japanese Administrative Database

Collaborators (4)

Kento Kitada

Dae Jung Kim

Masaomi Nangaku

Daisuke Yabe

Make your next move.